[go: up one dir, main page]

WO1999051264A3 - Cysteine-proteinases de leishmanies - Google Patents

Cysteine-proteinases de leishmanies Download PDF

Info

Publication number
WO1999051264A3
WO1999051264A3 PCT/GB1999/000889 GB9900889W WO9951264A3 WO 1999051264 A3 WO1999051264 A3 WO 1999051264A3 GB 9900889 W GB9900889 W GB 9900889W WO 9951264 A3 WO9951264 A3 WO 9951264A3
Authority
WO
WIPO (PCT)
Prior art keywords
cysteine proteinases
leishmania
leishmania cysteine
leishmania vaccine
proteinases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB1999/000889
Other languages
English (en)
Other versions
WO1999051264A2 (fr
Inventor
Jeremy Charles Mottram
Graham Herbert Coombs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Glasgow
Original Assignee
University of Glasgow
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Glasgow filed Critical University of Glasgow
Priority to EP99915864A priority Critical patent/EP1067961A2/fr
Priority to BR9909388-0A priority patent/BR9909388A/pt
Priority to APAP/P/2000/001945A priority patent/AP2000001945A0/en
Priority to IL13863999A priority patent/IL138639A0/xx
Publication of WO1999051264A2 publication Critical patent/WO1999051264A2/fr
Publication of WO1999051264A3 publication Critical patent/WO1999051264A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne un vaccin contre la leishmaniose, et plus particulièrement un vaccin contre la leishmaniose renfermant une ou plusieurs cystéine-protéinases actives ou inactives, qui se présentent notamment sous leur forme recombinante. Ce vaccin est destiné à être utilisé pour immuniser des mammifères, par exemple les chiens et/ou les humains.
PCT/GB1999/000889 1998-04-03 1999-04-06 Cysteine-proteinases de leishmanies Ceased WO1999051264A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP99915864A EP1067961A2 (fr) 1998-04-03 1999-04-06 Cysteine-proteinases de leishmanies
BR9909388-0A BR9909388A (pt) 1998-04-03 1999-04-06 Uso de pelo menos uma leishmania cisteìna proteinase, vacina, proteìna cpa do l. infantum, genes cpa e cpb do l. infantum, cpa ou cpb, e, uso das proteìnas cpa e/ou cpb ou das sequências de ácido nucléico do cpa e/ou cpb
APAP/P/2000/001945A AP2000001945A0 (en) 1998-04-03 1999-04-06 Leishmania cysteine proteinases.
IL13863999A IL138639A0 (en) 1998-04-03 1999-04-06 Leishmania cysteine proteinases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9807293.7A GB9807293D0 (en) 1998-04-03 1998-04-03 Leishmania cysteine proteinases
GB9807293.7 1998-04-03

Publications (2)

Publication Number Publication Date
WO1999051264A2 WO1999051264A2 (fr) 1999-10-14
WO1999051264A3 true WO1999051264A3 (fr) 1999-12-09

Family

ID=10829885

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/000889 Ceased WO1999051264A2 (fr) 1998-04-03 1999-04-06 Cysteine-proteinases de leishmanies

Country Status (6)

Country Link
EP (1) EP1067961A2 (fr)
AP (1) AP2000001945A0 (fr)
BR (1) BR9909388A (fr)
GB (1) GB9807293D0 (fr)
IL (1) IL138639A0 (fr)
WO (1) WO1999051264A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7736875B2 (en) 2000-09-08 2010-06-15 Prozymex A/S Dipeptidyl peptidase I crystal structure and its uses

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9706930D0 (en) 1997-04-04 1997-05-21 Univ Glasgow Leishmania vaccine
GB0008903D0 (en) * 2000-04-12 2000-05-31 Univ Glasgow Stage-specific sequences
AU3815102A (en) * 2000-09-08 2002-03-22 Prozymex As Dipeptidyl peptidase I crystal structure and its uses
WO2010000849A2 (fr) * 2008-07-04 2010-01-07 Institut De Recherche Pour Le Developpement (I.R.D.) Procédé de criblage de protéines secrétées conservées

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998044943A1 (fr) * 1997-04-04 1998-10-15 The University Court Of The University Of Glasgow Vaccin anti-leishmania

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998044943A1 (fr) * 1997-04-04 1998-10-15 The University Court Of The University Of Glasgow Vaccin anti-leishmania

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BEYRODT C G ET AL: "Characterization of an antigen from Leishmania amazonensis amastigotes able to elicit protective responses in a murine model.", INFECTION AND IMMUNITY, (1997 JUN) 65 (6) 2052-9., XP002118939 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; OMARA-OPYENE A L ET AL: "Molecular cloning, characterization and overexpression of two distinct cysteine protease cDNAs from Leishmania donovani chagasi.", XP002118942, retrieved from STN Database accession no. 1998156761 *
MOLECULAR AND BIOCHEMICAL PARASITOLOGY, (1997 DEC 1) 90 (1) 247-67. *
MOTTRAM J.C. ET AL: "A developmetally regulated cysteine proteinase gene of Leishmania mexicana", MOLECULAR MICROBIOLOGY, vol. 6, no. 14, 1992, pages 1925 - 1932, XP002118941 *
SOUZA A. ET AL: "Characterization of a multi-copy gene for a major stage specific cysteine proteinase of Leishmania mexicana", FEBS LETTERS, vol. 311, no. 2, 1992, pages 124 - 127, XP002118940 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7736875B2 (en) 2000-09-08 2010-06-15 Prozymex A/S Dipeptidyl peptidase I crystal structure and its uses

Also Published As

Publication number Publication date
EP1067961A2 (fr) 2001-01-17
IL138639A0 (en) 2001-10-31
GB9807293D0 (en) 1998-06-03
AP2000001945A0 (en) 2000-12-31
WO1999051264A2 (fr) 1999-10-14
BR9909388A (pt) 2000-12-05

Similar Documents

Publication Publication Date Title
MX265024B (es) Formulaciones de glifosato de potasio.
ATE289640T1 (de) Amidofunktionelle aminopolydiorganosiloxane
WO2002069846A3 (fr) Gaine de pose de filtre de protection contre l'embolie
AU2001257312A1 (en) Improved face mask structure
MXPA02010787A (es) Peptidos modificados como agentes terapeuticos.
WO2002102586A3 (fr) Composites cellulose et polymere et procede de fabrication
AU8738401A (en) Novel kallikrein gene
WO2001054659A3 (fr) Composition cosmetique amincissante comprenant un extrait de plante contenant un peptide natiuretique
LT99131A (en) Compounds and compositions for treating diseases associated with serine protease, particularly tryptase, acitivity
ZA200403803B (en) Selective targeting of apoptotic cells.
WO2002062304A3 (fr) Agents cosmetiques et/ou pharmaceutiques
WO1999051264A3 (fr) Cysteine-proteinases de leishmanies
MXPA02002565A (es) Procedimiento para hacer hidrolizados de proteina a partir de peptona anumal y para conservar la mucosa.
AP9901666A0 (en) Leishmania vaccine.
WO2002046225A3 (fr) Utilisation de sarp-1 dans le traitement et/ou la prevention de la sclerodermie
WO2004110469A3 (fr) Nouvelles formulations
WO2002085930A3 (fr) Immunomodulants provenant de vers parasites et procede pour leur separation
WO2002087604A3 (fr) Preparations de vitamine e en combinaison avec l'afamine
IL164901A0 (en) Optically active beta-aminoketones, optically active 1,3-aminoalcohols and processes for preparing them
MXPA03008099A (es) Composicion topica que comprende un agente enlazante cosmetico de dieno constituido por un 1,2-heteroatomo.
AU3519299A (en) Human casb12 polypeptide, a serine protease
WO2002038122A3 (fr) Compositions exemptes de protease, comprenant une glycosidase
WO2003020767A3 (fr) Anticorps anti-caspase-8, preparation et utilisation de ces anticorps
AU2002216617A1 (en) Cloning endangered and extinct species
FR2719647B1 (fr) Soupape, notamment soupape à vide.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): BR IL MX US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): BR IL MX US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1999915864

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 138639

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/009706

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 1999915864

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999915864

Country of ref document: EP